​

Allogene Therapeutics (ALLO) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

ALLO Stock Forecast

Allogene Therapeutics (ALLO) stock forecast, based on 30 Wall Street analysts, predicts a 12-month average price target of $6.43, with a high of $9.00 and a low of $3.85. This represents a 178.35% increase from the last price of $2.31.

$2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $6.43 Low: $3.85 Last Closed Price: $2.31

ALLO Stock Rating

Allogene Therapeutics stock's rating consensus is Buy, based on 30 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (63.33%), 10 Hold (33.33%), 1 Sell (3.33%), and 0 Strong Sell (0.00%).

Buy
Total 30 1 10 19 Strong Sell Sell Hold Buy Strong Buy

ALLO Price Target Upside V Benchmarks

TypeNameUpside
StockAllogene Therapeutics178.35%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts222
Avg Price Target$6.43$6.43$6.43
Last Closing Price$2.31$2.31$2.31
Upside/Downside178.35%178.35%178.35%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 263101-115
Mar, 263101-115
Feb, 263101-115
Jan, 26292-114
Dec, 25292-114
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 14, 2026Bernstein$3.85$3.0625.82%66.67%
Apr 14, 2026Robert W. Baird$9.00$3.06194.12%289.61%
May 16, 2024Debjit ChattopadhyayH.C. Wainwright$9.00$2.98202.01%289.61%
May 14, 2024Kalpit PatelB.Riley Financial$7.00$2.90141.38%203.03%
Jun 13, 2022Jack AllenRobert W. Baird$11.00$9.7412.94%376.19%
Jan 03, 2022Michael SchmidtGuggenheim$35.00$15.29128.91%1415.15%
Dec 03, 2021John NewmanCanaccord Genuity$55.00$17.62212.15%2280.95%
Oct 08, 2021Mark BreidenbachOppenheimer$40.00$13.13204.65%1631.60%
Oct 08, 2021Jason GerberryBank of America Securities$32.00$13.13143.72%1285.28%
Oct 08, 2021Biren AminJefferies$30.00$13.13128.48%1198.70%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 15, 2026JefferiesBuyBuyhold
Apr 14, 2026BernsteinMarket PerformMarket Performhold
Apr 14, 2026H.C. WainwrightBuyBuyhold
Apr 14, 2026CitigroupOutperformOutperformhold
Jan 09, 2026CitigroupMarket PerformOutperformupgrade
Jan 07, 2026UBSBuyinitialise
May 14, 2025CitigroupBuyMarket Performdowngrade
Oct 30, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024CitigroupBuyBuyhold
Jun 17, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.34$-2.38$-2.09$-1.32$-0.87---
Avg Forecast$-1.96$-2.37$-2.01$-1.33$-1.35$-1.45$-1.51$-0.85
High Forecast$-0.74$-1.00$-1.89$-1.27$-1.02$-0.95$-0.91$-0.40
Low Forecast$-2.96$-2.71$-2.16$-1.43$-1.67$-2.01$-2.46$-1.05
Surprise %-31.63%0.42%3.98%-0.75%-35.56%---

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$114.09M$156.00K$95.00K$22.00K----
Avg Forecast$38.32M$177.95K$134.71K$23.75K$26.67K$11.11K$46.00M$240.57M
High Forecast$53.31M$197.72K$149.67K$39.58K$31.37K$13.07K$47.57M$283.03M
Low Forecast$19.99M$98.86K$104.77K$7.92K$15.69K$6.54K$44.43M$141.51M
Surprise %197.75%-12.34%-29.48%-7.37%----

Net Income Forecast

$-400M $-330M $-260M $-190M $-120M $-50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-182.05M$-340.41M$-327.26M$-257.59M$-190.89M---
Avg Forecast$-275.94M$-300.14M$-327.26M$-212.17M$-210.95M$-232.82M$-336.34M$-133.39M
High Forecast$-220.75M$-240.11M$-261.81M$-199.87M$-160.57M$-149.45M$-142.92M$-61.99M
Low Forecast$-331.13M$-360.17M$-392.72M$-224.47M$-261.32M$-316.20M$-385.39M$-163.99M
Surprise %-34.02%13.42%-21.41%-9.51%---

ALLO Forecast FAQ

Is Allogene Therapeutics stock a buy?

Allogene Therapeutics stock has a consensus rating of Buy, based on 30 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Allogene Therapeutics is a favorable investment for most analysts.

What is Allogene Therapeutics's price target?

Allogene Therapeutics's price target, set by 30 Wall Street analysts, averages $6.43 over the next 12 months. The price target range spans from $3.85 at the low end to $9 at the high end, suggesting a potential 178.35% change from the previous closing price of $2.31.

How does Allogene Therapeutics stock forecast compare to its benchmarks?

Allogene Therapeutics's stock forecast shows a 178.35% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Allogene Therapeutics over the past three months?

  • April 2026: 20.00% Strong Buy, 66.67% Buy, 6.67% Hold, 0% Sell, 6.67% Strong Sell.
  • March 2026: 20.00% Strong Buy, 66.67% Buy, 6.67% Hold, 0% Sell, 6.67% Strong Sell.
  • February 2026: 20.00% Strong Buy, 66.67% Buy, 6.67% Hold, 0% Sell, 6.67% Strong Sell.

What is Allogene Therapeutics’s EPS forecast?

Allogene Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.45, marking a 66.67% increase from the reported $-0.87 in 2025. Estimates for the following years are $-1.51 in 2027, and $-0.85 in 2028.

What is Allogene Therapeutics’s revenue forecast?

Allogene Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $11.11K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $46M, and $240.57M for 2028.

What is Allogene Therapeutics’s net income forecast?

Allogene Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-233M, representing an 21.97% increase from the reported $-191M in 2025. Projections indicate $-336M in 2027, and $-133M in 2028.